AZ Confident New Cancer Drugs Can Drive Return To Sales Growth

The drugs major is looking to return to sales growth in 2018 and believes that its oncology division will be the main driver as the last wave of patent expiries ebbs away.

Darts
AZ says it is on target to getting significant sales growth from its cancer drugs • Source: Shutterstock

AstraZeneca PLC has unveiled third-quarter results Nov. 9 which were in line with expectations and also focused on the advances its cancer treatments have been making in the clinic and commercially.

One treatment that received much attention on conference calls to discuss the results was the PD-1/L1 inhibitor Imfinzi (durvalumab), a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.